Antipsychotics for treatment of delirium in hospitalised non-ICU patients

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 6, 2018, Pages

  Burry, Lisa ^a   Mehta, Sangeeta ^b   Perreault, Marc M ^c   Luxenberg, Jay S ^d   Siddiqi, Najma ^e   Hutton, Brian ^f   Fergusson, Dean A ^f   Bell, Chaim ^b   Rose, Louise ^g  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d On Lok   (United States)

^e UNIVERSITY OF YORK   (United Kingdom)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE;

AGITATION; ATRIOVENTRICULAR BLOCK; BEDTIME DOSAGE; DELIRIUM; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HOSPITAL MORTALITY; HOSPITAL PATIENT; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ADULT; FEMALE; HOSPITALIZATION; MALE; META ANALYSIS; MORTALITY; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DELIRIUM; FEMALE; HALOPERIDOL; HOSPITALIZATION; HUMANS; MALE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE;

EID: 85048764882     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD005594.pub3     Document Type: Review

References (129)

1. Agar M, Lawlor P, Quinn S, Draper B, Caplan G, Rowett D, et al. Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial. JAMA Internal Medicine 2016;177(1):34-42. 8662082
2. Breitbart W, Marotta R, Platt MM, Weisman H, Derevenco M, Grau C, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. American Journal of Psychiatry 1996;153(2):231-7. 8662084
3. Grover S, Kumar V, Chakrabarti S. Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium. Journal of Psychosomatic Research 2011;71(4):277-81. 8662086
4. Grover S, Mahajan S, Chakrabarti S, Avasthi A. Comparative effectiveness of quetiapine and haloperidol in delirium: a single blind randomized controlled study. World Journal of Psychiatry 2016;6(3):365-71. 8662088
5. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004;45(4):297-301. 8662090
6. Hu H, Deng W, Yang H. A prospective random control study: comparison of olanzapine and haloperidol in senile delirium. Chongging Medical Journal 2004;8(7):1234-7. 8662091
7. Lin CJ, Sun FJ, Fang CK, Chen HW, Lai YL. An open trial comparing haloperidol with olanzapine for the treatment of delirium in palliative and hospice center cancer patients. Journal of Internal Medicine of Taiwan 2008;19:346-54. 8662093
8. Maneeton B, Maneeton N, Srisurapanont M, Chittawatanarat K. Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial. Drug Design, Development and Therapy 2013;7:657-67. 8662095
9. Tahir TA, Eeles E, Karapareddy V, Muthuvelu P, Chapple S, Phillips B, et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Journal of Psychosomatic Research 2010;69(5):485-90. 8662097
10. Al-Qadheeb NS, Skrobik Y, Schumaker G, Pacheco MN, Roberts RJ, Ruthazer RR, et al. Randomized ICU trials do not demonstrate an association between interventions that reduce delirium duration and short-term mortality: a systematic review and meta-analysis. Critical Care Medicine 2014;42(6):1442-54. 8662099
11. Atalan N, Sevim ME, Akgun S, Fazligullari O, Basaran C. Morphine is a reasonable alternative to haloperidol in the treatment of postoperative hyperactive-type delirium after cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia 2013;27(5):933-8. 8662101
12. Bakri MH, Ismail EA, Ibrahim A. Comparison of dexmedetomidine or ondansetron with haloperidol for treatment of postoperative delirium in trauma patients admitted to intensive care unit: randomized controlled trial. Anaesthesia, Pain & Intensive Care 2015;19(2):118-23. 8662103
13. Devlin JW, Robert RJ, Fong JJ, Skrobik Y, Riker RR, Hill NS, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Critical Care Medicine 2010;38(2):419-27. 8662105
14. Girard TD, Pandharipande PP, Carson SS, Schmidt GA, Wright PE, Canonico AE, et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Critical Care Medicine 2010;38(2):428-37. 8662107
15. Hakim SM, Othman AI, Naoum DO. Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: a randomized trial. Anesthesiology 2012;116(5):987-97. 8662109
16. Jung SW, Kim KS. A randomized controlled, pilot study of aripiprazole in the treatment of delirium. European Neuropsychopharmacology 2009;19(Supp 3):S553-4. 8662111
17. Jung SW, Sakong JK, Lee JY, Choi YR, Suh HS. Comparison between effectiveness of quetiapine and risperidone for treatment of delirium in hospitalized patients. International Journal of Neuropsychopharmacology 2010;13:96. 8662113
18. Kim SW, Yoo JA, Lee SY, Kim SY, Bae KY, Yang SJ, et al. Risperidone versus olanzapine for the treatment of patients with delirium. Human Psychopharmacology 2010;25(4):298-302. 8662115
19. Lee KU, Won WY, Lee HK, Kweon YS, Lee CT, Pae CU, et al. Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. International Clinical Psychopharmacology 2005;20(6):e311-e314. 8662117
20. Page VJ, Ely EW, Gates S, Zhao XB, Alce T, Shintani A, et al. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine 2013;1(7):515-23. 8662119
21. Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WRTSJ, Bellomo R. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Critical Care 2009;13(3):R75. 8662121
22. Reade MC, Eastwood GM, Bellomo R, Bailey M, Bersten A, Cheung B, et al. Effect of dexmedetomidine added to standard care on ventilator-free time in patients with agitated delirium: a randomized clinical trial. JAMA 2016;315(14):1460-8. 8662123
23. Sakong JK, Jung SW, Kim JS, Koo BH. Comparison between effectiveness of aripiprazole and risperidone for treatment of delirium in hospitalized patients. European Neuropsychopharmacology 2010;20:S568-9. 8662125
24. Skrobik Y, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Medicine 2004;30(3):444-9. 8662127
25. Djokic G, Zivkovic N, Pavicevic D, et al. Risperidone vs. haloperidol in treatment of delirium superimposed on dementia. European Neuropsychopharmacology 2008;18 Suppl 4:S504-5. 8662129
26. Jung Jin K, Hyun Kook L, Chi Un P, Chang Uk L, In Ho P, Chul L. Comparison of intramuscular olanzapine and haloperidol for the treatment of delirium. European Psychiatry 2009;24:S1006. 8662131
27. Lee J. Comparison of efficacy and side effects between aripiprazole and haloperidol in the treatment of delirium. International Psychogeriatrics 2013;1:S132-3. 8662133
28. Nakamura J, Uchimura N, Yamada S, Nakazawa Y. Does plasma free-3-methoxy-4-hydroxyphenyl(ethylene)glycol increase in the delirious state? A comparison of the effects of mianserin and haloperidol on delirium. International Clinical Psychopharmacology 1997;12(3):147-52. 8662135
29. NCT02345902. Treatment of hypoactive delirium and outcome measures. clinicaltrials.gov/ct2/show/NCT02345902?term=NCT02345902&rank=1 (first received 26 January 2015). 8662137
30. American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. American Journal of Psychiatry 1999;156 Suppl:1-20.
31. Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Critical Care Medicine 2013;41(1):263-306.
32. Boettger SB, Breitbart W, Passik S. Haloperidol and risperidone in the treatment of delirium and its subtypes. European Journal of Psychiatry 2011;25(2):59-67.
33. Boettger S, Friedlander M, Breitbart W, Passik S. Aripiprazole and haloperidol in the treatment of delirium. Australian and New Zealand Journal of Psychiatry 2011;45(6):477-82.
34. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. Journal of Pain and Symptom Management 1997;13(3):128-37.
35. Breitbart W, Gibson C, Tremblay A. The delirium experience: delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses/caregivers, and their nurses. Psychosomatics 2002;43(3):183-94.
36. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics 2002;43(3):175-82.
37. Briskman I, Dubinski R, Barak Y. Treating delirium in a general hospital: a descriptive study of prescribing patterns and outcomes. International Psychogeriatrics 2010;22(2):328-31.
38. British Geriatric Society. Clinical guidelines for the prevention, diagnosis and management of delirium in older people in hospital. www.bgs.org.uk/Publications/Clinical%20Guidelines/clinical_1-2_fulldelirium.htm (accessed 1 December 2014).
39. Bruera E, Bush SH, Willey J, Paraskevopoulos T, Li Z, Palmer JL, et al. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer 2009;115(9):2004-12.
40. Burry L, Mehta S, Williamson DR, Hutton B, Ely EW, Adhikari NKJ, et al. Pharmacological interventions for the treatment of delirium in critically ill patients. Cochrane Database of Systematic Reviews of Interventions 2015, Issue 6. [DOI: 10.1002/14651858.CD011749]
41. Buss MK, Vanderwerker LC, Inouye SK, Zhang B, Block SD, Prigerson HG. Associations between caregiver-perceived delirium in patients with cancer and generalized anxiety in their caregivers. Journal of Palliative Medicine 2007;10(5):1083-93.
42. Buurman BM, Hoogerduijn JG, De Haan RJ, Abu-Hanna A, Lagaay AM, Verhaar HJ, et al. Geriatric conditions in acutely hospitalized older patients: prevalence and one-year survival and functional decline. PLOS One 2011;6(11):e26951.
43. Carnes M, Howell T, Rosenberg M, Francis J, Hildebrand C, Knuppel J. Physicians vary in approaches to the clinical management of delirium. Journal of the American Geriatrics Society 2003;51(2):234-9.
44. Clinical Epidemiology and Health Service Evaluation Unit, Melbourne Health and the Australian Health Ministers' Health Care of Older Australians Standing Committee. Clinical Practice Guidelines for the Management of Delirium in Older People. www.health.vic.gov.au/acute-agedcare/ (accessed 1 February 2015).
45. Cerejeira J, Firmino HC, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathologica 2010;119(6):737-54.
46. Cohen MZ, Pace EA, Kaur G, Bruera E. Delirium in advanced cancer leading to distress in patients and family caregivers. Journal of Palliative Care 2009;25(3):164-71.
47. Cole MG, Ciampi A, Belzile E, Zhong L. Persistent delirium in older hospital patients: a systematic review of frequency and prognosis. Age & Ageing 2009;38(1):19-26.
48. DeMets DL. Methods for combining randomized clinical trials. Statistics in Medicine 1987;6(3):341-50.
49. Devlin JW, Skrobik Y, Riker RR, Hinderleider E, Roberts RJ, Fong JJ, et al. Impact of quetiapine on resolution of individual delirium symptoms in critically ill patients with delirium: a post-hoc analysis of a double-blind, randomized, placebo-controlled study. Critical Care 2011;15(5):R215.
50. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, 1994.
51. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington: American Psychiatric Association, 2000.
52. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington: American Psychiatric Association, 2013.
53. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
54. Thomson Reuters. EndNote (Endnote Version X6). Calsbad, CA, USA: Thomson Reuters, 2012.
55. Flacker JM, Lipsitz LA. Neural mechanisms of delirium: current hypotheses and evolving concepts. Journals of Gerontology. Series A: Biological Sciences and Medical Sciences 1999;54(6):B239-46.
56. Fosnight S. Delirium in the elderly. In: Richardson M, Chant C, Chessman KH, Finks SW, Hemstreet BA, Hume AL, et.al editor(s). Pharmacotherapy Self-Assessment Program. 7th Edition. Lenexa: American College of Clinical Pharmacy, 2011:73-95.
57. Gaudreau JD, Gagnon P. Psychotogenic drugs and delirium pathogenesis: the central role of the thalamus. Medical Hypotheses 2005;64(3):471-5.
58. Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine 2007;146(11):775-86.
59. Gillick MR, Serrell NA, Gillick LS. Adverse consequences of hospitalization in the elderly. Social Science and Medicine 1982;16(10):1033-8.
60. Gleason OC. Delirium. American Family Physician 2003;67(5):1027-34.
61. Evidence Prime, Inc. GRADEpro Guideline Development Tool. Version (accessed prior to 17 May 2018). Hamilton (ON): McMaster University, 2015. [gradepro.org]
62. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
63. Han JH, Shintani A, Eden S, Morandi A, Solberg LM, Schnelle J, et al. Delirium in the emergency department: an independent predictor of death within 6 months. Annals of Emergency Medicine 2010;56(3):244-52.
64. Hatta K, Kishi Y, Wada K, Odawara T, Takeuchi T, Shiganami T, et al. Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients: a prospective observational study. International Journal of Geriatric Psychiatry 2014;29(3):253-62.
65. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
66. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
67. Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. Journals of Gerontology: Series A 2008;63(7):764-72.
68. Hua H, Wei D, Hui Y, Yu L. Olanzapine and haloperidol for senile delirium: a randomized controlled observation. Chinese Journal of Clinical Rehabilitation 2006;10(42):188-90.
69. Institute for Healthcare Improvement. Sedation, delirium, and mobility. www.ihi.org/Pages/default.aspx (accessed 3 February 2015).
70. Inouye SK, Van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Annals of Internal Medicine 1990;113(12):941-8.
71. Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. Journal of the American Medical Association 1996;275(11):852-7.
72. Inouye SK, Rushing JT, Foreman MD, Palmer RM, Pompei P. Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. Journal of General Internal Medicine 1998;13(4):234-42.
73. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. American Journal of Medicine 1999;106(5):565-73.
74. Inouye SK, Foreman MD, Mion LC, Katz KH, Cooney LM Jr. Nurses' recognition of delirium and its symptoms: comparison of nurse and researcher ratings. Archives of Internal Medicine 2001;161(20):2467-73.
75. Inouye SK. Delirium in older persons. New England Journal of Medicine 2006;354(11):1157-65.
76. Inouye SK, Baker DI, Fugal P, Bradley EH, Project HD. Dissemination of the hospital elder life program: implementation, adaptation, and successes. Journal of the American Geriatrics Society 2006;54(10):1492-9.
77. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet 2014;383(9920):911-22.
78. Ito T, Okubo Y. Aripiprazole in the treatment of hypoactive subtype of delirium with terminal cancer patients. Proceedings of the Academy of Psychosomatic Medicine. 2007:31.
79. Kakuma R, Du Fort GG, Arsenault L, Perrault A, Platt RW, Monette J, et al. Delirium in older emergency department patients discharged home: effect on survival. Journal of the American Geriatric Society 2003;51(4):443-50.
80. Kim KY, Bader GM, Kotlyar V, Gropper D. Treatment of delirium in older adults with quetiapine. Journal of Geriatric Psychiatry and Neurology 2003;16(1):29-31.
81. Kishi T, Hirota T, Matsunaga S, Iwata N. Antipsychotic medications for the treatment of delirium: a systematic review and meta-analysis of randomised controlled trials. J Neurology, Neurosurgery, & Psychiatry 2016;87:767-74.
82. Leonard M, Adamis D, Saunders J, Trzepacz P, Meagher D. A longitudinal study of delirium phenomenology indicates widespread neural dysfunction. Palliative and Supportive Care 2015;13(2):187-96.
83. Leslie DL, Zhang Y, Holford TR, Bogardus ST, Leo-Summers LS, Inouye SK. Premature death associated with delirium at 1-year follow-up. Archives of Internal Medicine 2005;165(14):1657-62.
84. Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. Archives of Internal Medicine 2008;168(1):27-32.
85. Levkoff SE, Evans DA, Liptzin B, Cleary PD, Lipsitz LA, Wetle TT, et al. Delirium. The occurrence and persistence of symptoms among elderly hospitalized patients. Archives of Internal Medicine 1992;152(2):334-40.
86. Lundstrom M, Edlund A, Karlsson S, Brannstrom B, Bucht G, Gustafson Y. A multifactorial intervention program reduces the duration of delirium, length of hospitalization, and mortality in delirious patients. Journal of the American Geriatrics Society 2005;53(4):622-8.
87. Maclullich AM, Anand A, Davis DH, Jackson T, Barugh AJ, Hall RJ, et al. New horizons in the pathogenesis, assessment and management of delirium. Age & Ageing 2013;42(6):667-74.
88. McCusker J, Cole M, Dendukuri N, Belzile E, Primeau F. Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study. Canadian Medical Association Journal 2001;165(5):575-83.
89. McCusker J, Cole M, Abrahamowicz M, Primeau F, Belzile E. Delirium predicts 12-month mortality. Archives of Internal Medicine 2002;162(4):457-63.
90. McCusker J, Cole M, Dendukuri N, Han L, Belzile E. The course of delirium in older medical inpatients: a prospective study. Journal of General Internal Medicine 2003;18(9):696-704.
91. Meagher DJ. Impact of an educational workshop upon attitudes towards pharmacotherapy for delirium. International Psychogeriatrics 2010;22(6):938-46.
92. Meagher D, Adamis D, Trzepacz P, Leonard M. Features of subsyndromal and persistent delirium. British Journal of Psychiatry 2012;200(1):37-44.
93. Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. American Journal of Alzheimer's Disease and Other Dementias 2011;26(1):10-28.
94. Morita T, Hirai K, Sakaguchi Y, Tsuneto S, Shima Y. Family-perceived distress from delirium-related symptoms of terminally ill cancer patients. Psychosomatics 2004;45(2):107-13.
95. Neelon VJ, Champagne MT, Carlson JR, Funk SG. The NEECHAM Confusion Scale: construction, validation, and clinical testing. Nursing Research 1996;45(6):324-30.
96. Neufeld KJ, Yue J, Robinson TN, Inouye SK, Needham DM. Antipsychotic medication for prevention and treatment of delirium in hospitalized adults: a systematic review and meta-analysis. Journal of the American Geriatrics Society 2016;64(4):705-14.
97. National Institute for Health and Clinical Excellence. Delirium: Diagnosis, Prevention, and Management (Clinical Guideline 103). www.nice.org.uk/CG103 (accessed 4 January 2015).
98. Organization for Economic Co-operation and Development. OECD Health Data. www.oecd.org/health/ (accessed 3 December 2014).
99. Parellada E, Baeza I, De Pablo J, Martinez G. Risperidone in the treatment of patients with delirium. Journal of Clinical Psychiatry 2004;65(3):348-53.
100. Partridge JS, Martin FC, Harari D, Dhesi JK. The delirium experience: what is the effect on patients, relatives and staff and what can be done to modify this?. International Journal of Geriatric Psychiatry 2013;28(8):804-12.
101. Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS. Prognostic significance of delirium in frail older people. Dementia and Geriatric Cognitive Disorders 2005;19(2-3):158-63.
102. Platt MM, Breitbart W, Smith M, Marotta R, Weisman H, Jacobsen PB. Efficacy of neuroleptics for hypoactive delirium. Journal of Neuropsychiatry and Clinical Neuroscience 1994;6(1):66-7.
103. Pompei P, Foreman M, Rudberg MA, Inouye SK, Braund V, Cassel CK. Delirium in hospitalized older persons: outcomes and predictors. Journal of the American Geriatrics Society 1994;42(8):809-15.
104. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine 2009;360(3):225-35.
105. Royal College of Psychiatrists. The prevention, diagnosis and management of delirium in older people (National Guidelines). www.rcplondon.ac.uk/sites/default/files/concise-delirium-2006.pdf (accessed 11 December 2014).
106. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
107. Rizzo JA, Bogardus ST Jr, Leo-Summers L, Williams CS, Acampora D, Inouye SK. Multicomponent targeted intervention to prevent delirium in hospitalized older patients: what is the economic value?. Medical Care 2001;39(7):740-52.
108. Rolfson D. The causes of delirium. In: Lindesay JRK, Macdonald A editor(s). Delirium in Old Age. Oxford: Oxford University Press, 2002:101-22.
109. Rose L, Agar M, Burry LD, Campbell N, Clarke M, Lee J, et al. Development of core outcome sets for effectiveness trials of interventions to prevent and/or treat delirium (Del-COrS): study protocol. BMJ Open 2017;7:e016371. [PUBMED: 28928181]
110. Rothschild JM, Bates DW, Leape LL. Preventable medical injuries in older patients. Archives of Internal Medicine 2000;160(18):2717-28.
111. Rudolph JL, Marcantonio ER. Review articles: postoperative delirium: acute change with long-term implications. Anesthesia and Analgesia 2011;112(5):1202-11.
112. Safer Healthcare Now!. Prevention and management of delirium. www.saferhealthcarenow.ca/EN/Interventions/DeliriumPrevention/Pages/default.aspx (accessed 30 November 2014).
113. Salluh JI, Soares M, Teles JM, Ceraso D, Raimondi N, Nava VS, et al. Delirium epidemiology in critical care (DECCA): an international study. Critical Care 2010;14(6):R10.
114. Sasaki Y, Matsuyama T, Inoue S, Sunami T, Inoue T, Denda K, et al. A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. Journal of Clinical Psychiatry 2003;64(11):1316-21.
115. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005;294(15):1934-43.
116. Thomas C, Hestermann U, Kopitz J, Plaschke K, Oster P, Driessen M, et al. Serum anticholinergic activity and cerebral cholinergic dysfunction: an EEG study in frail elderly with and without delirium. BMC Neuroscience 2008;9:86.
117. Traube C, Silver G, Kearney J, Patel A, Atkinson TM, Yoon MJ, et al. Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU. Critical Care Medicine 2014;42(3):656-63.
118. Trzepacz PT, Baker RW, Greenhouse J. A symptom rating scale for delirium. Psychiatry Research 1988;23(1):89-97.
119. Trzepacz PT. Update on the neuropathogenesis of delirium. Dementia and Geriatric Cognitive Disorders 1999;10(5):330-4.
120. Trzepacz PT. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Seminars in Clinical Neuropsychiatry 2000;5(2):132-48.
121. Trzepacz PT, Mittal D, Torres R, Kanary K, Norton J, Jimerson N. Validation of the Delirium Rating Scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. Journal of Neuropsychiatry and Clinical Neurosciences 2001;13(2):229-42.
122. Van der Cammen TJ, Tiemeier H, Engelhart MJ, Fekkes D. Abnormal neurotransmitter metabolite levels in Alzheimer patients with a delirium. International Journal of Geriatric Psychiatry 2006;21(9):838-43.
123. Vasilevskis EE, Han JH, Hughes CG, Ely EW. Epidemiology and risk factors for delirium across hospital settings. Best Practice & Research Clinical Anaesthesiology 2012;26:277-87.
124. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine 2005;353(22):2335-41.
125. Watt DBD, Koziol LF. Delirium. In: Noggle C, Dean R editor(s). The Neuropsychology of Psychopathology. New York: Springer Publishing Company, 2013:425-40.
126. WHO Regional Office for Europe, World Health Organization. European hospital morbidity database. data.euro.who.int/hmdb/index.php (accessed 16 October 2014).
127. Witlox J, Eurelings LS, De Jonghe JF, Kalisvaart KJ, Eikelenboom P, Van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. Journal of the American Medical Association 2010;304(4):443-51.
128. Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment. Drugs & Aging 1997;10(5):367-83.
129. Lonergan E, Britton AM, Luxenberg J. Antipsychotics for delirium. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005594.pub2]